While crucial for health and longevity, large volumes and poor palatability discourage patients, so NTC completed studies on Kleerkol® to make this step easier, more tolerable, and to reduce reluctance to colonoscopy improving compliance to screening program.

NTC strenghtens its position in Italy by introducing an aflibercept biosimilar, expanding treatment access for neovascular retinal diseases and its product portfolio.

NTC has obtained MDR certification for 20 medical devices, strengthening the value of its portfolio and safeguarding access to the European market.

In ten years, NTC has built a global presence with over 300 distributors in more than 100 countries, over 40 million units distributed each year, and team growth from less than 40 to 134 people, establishing itself as one of the leading European players in ophthalmic therapeutic solutions.